Compare Illumina, Inc. (ILMN) vs Nebius Group NV (NBIS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Illumina, Inc. vs Nebius Group NV — how do they compare? Illumina, Inc. trades at $191.6 (market cap $27.94B), while Nebius Group NV trades at $213.02 (market cap $46.37B). The key difference: Nebius Group NV is the larger of the two by market cap, and Illumina, Inc. is trading nearer its 52-week high, Nebius Group NV nearer its low. Which is the better fit depends on your goals.
| ILMN | NBIS | |
|---|---|---|
Market Cap | $27.94B | $46.37B |
Sector | Health | Technology |
52-Week High | $194.33 | $286.69 |
52-Week Low | $91.00 | $50.40 |
Enterprise Value | $29.33B | $46.56B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Illumina (ILMN) trades at $185.36, down 0.69% on the day, with a bullish technical signal from moving averages. The stock shows strong profitability with a 19.42% net income margin and has beaten EPS estimates for three consecutive quarters. Recent news highlights expansion of the Billion Cell Atlas program and upcoming Q2 2026 earnings on July 30.
Outlook remains positive with 51% analyst buy ratings, though the current price exceeds the $178 consensus target. Key risks include competitive pressure from Roche's new sequencer and China market weakness. Earnings growth and cost control initiatives support upside potential, but valuation multiples suggest limited near-term appreciation.
NBIS trades at $182.62, up 2.76% today, with a bullish technical signal despite recent volatility. The company reported Q1 2026 EPS of -$0.23, beating expectations, and secured a $775 million debt facility to accelerate AI cloud expansion. Analyst consensus remains strongly positive with an $242 price target, though high valuation ratios (P/E 68.61, P/S 53.73) reflect growth expectations.
Outlook is supported by robust AI demand and a debt-free balance sheet, but risks include intense competition and execution challenges in scaling infrastructure. The stock offers significant upside if growth targets are met, yet remains sensitive to sector sentiment shifts and capital expenditure pressures.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Illumina, Inc.
Illumina provides tools and services to analyze genetic material with life science and clinical lab applications. The company generates over 90% of its revenue from sequencing instruments, consumables, and services. Illumina's high-throughput technology enables whole genome sequencing in humans and other large organisms. Its lower throughput tools enable applications that require smaller data outputs, such as viral and cancer tumor screening. Illumina also sells microarrays (less than 10% of sales) that enable lower-cost, focused genetic screening with primarily consumer and agricultural applications.
Read more on ILMN →About Nebius Group NV
Nebius Group N.V. is a technology company specializing in AI, machine learning, and cloud computing solutions. The company provides a range of enterprise-level cloud services, including large-scale data processing, advanced analytics, and AI model development and deployment. Nebius Group focuses on serving businesses that require high-performance, scalable, and secure infrastructure to handle complex computational tasks and accelerate their digital transformation.
Read more on NBIS →
